Samik Pharmaceutical (A014950) Stock Overview
Develops and manufactures pharmaceuticals. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
A014950 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Samik Pharmaceutical Company LTD. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩13,850.00 |
| 52 Week High | ₩25,050.00 |
| 52 Week Low | ₩6,650.00 |
| Beta | 0 |
| 1 Month Change | -15.29% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 42.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| A014950 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 4.9% | 1.1% | 4.3% |
| 1Y | n/a | 22.8% | 71.1% |
Return vs Industry: Insufficient data to determine how A014950 performed against the KR Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how A014950 performed against the KR Market.
Price Volatility
| A014950 volatility | |
|---|---|
| A014950 Average Weekly Movement | 23.3% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A014950's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: Insufficient data to determine A014950's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1973 | n/a | Choong-Hwan Lee | www.samik.co.kr |
Samik Pharmaceutical Company LTD. develops and manufactures pharmaceuticals. The company offers oral therapeutic pharmaceuticals.
Samik Pharmaceutical Company LTD. Fundamentals Summary
| A014950 fundamental statistics | |
|---|---|
| Market cap | ₩127.02b |
| Earnings (TTM) | ₩3.27b |
| Revenue (TTM) | ₩58.88b |
Is A014950 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A014950 income statement (TTM) | |
|---|---|
| Revenue | ₩58.88b |
| Cost of Revenue | ₩16.90b |
| Gross Profit | ₩41.97b |
| Other Expenses | ₩38.70b |
| Earnings | ₩3.27b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 356.25 |
| Gross Margin | 71.29% |
| Net Profit Margin | 5.55% |
| Debt/Equity Ratio | 0% |
How did A014950 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/04 23:24 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Samik Pharmaceutical Company LTD. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.